{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:00:17Z","timestamp":1790834417840,"version":"4.1.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metastatic castration-resistant prostate cancer (mCRPC) treatment commonly includes first-line (1L) androgen receptor pathway inhibitors (ARPIs) followed by second-line (2L) taxane-based chemotherapy. Adverse events (AEs) may lead to early taxane discontinuation, which can negatively affect outcomes and costs. This retrospective observational study assessed real-world outcomes, AEs, and costs of 2L taxane therapy by number of cycles among patients with mCRPC previously treated with a 1L ARPI; outcomes were compared with patients receiving 2L ARPI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Overall survival (OS; overall and by number of taxane cycles received) was determined for 2L taxane and compared with 2L ARPI using the Flatiron Health electronic health record database (Jul 1, 2012, to Jun 30, 2020). Taxane-related AEs and associated costs were estimated using the IQVIA PharMetrics\u00ae Plus claims database (Jan 1, 2013, to Aug 31, 2021).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall, 2L ARPI (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009473) vs. taxane (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009214) was associated with longer median OS (15.4 vs. 13.6\u00a0months). Patients receiving\u2009&gt;\u20098 (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200948) vs.\u2009\u2264\u20098 taxane cycles (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009166) had longer median OS (18.4 vs. 11.9\u00a0months;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.006). Patients receiving\u2009&gt;\u20098 vs.\u2009\u2264\u20098 taxane cycles were also more likely to experience an AE (95% vs. 88%) but had lower mean AE-related total healthcare costs per patient per month ($3,429 vs. $6,334).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients who received\u2009&gt;\u20098 cycles of 2L taxane had longer observed survival. However, these results are subject to selection bias and immortal time bias. Prospective or time-adjusted analyses are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10147-026-03102-2","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T16:42:08Z","timestamp":1782405728000},"page":"1451-1471","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world clinical outcomes and economic burden of discontinuation of taxane therapy among patients with metastatic castration-resistant prostate cancer"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5767-0548","authenticated-orcid":false,"given":"Neal","family":"Shore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7878-5539","authenticated-orcid":false,"given":"Jennifer","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9374-6180","authenticated-orcid":false,"given":"Barinder","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6315-7121","authenticated-orcid":false,"given":"Amrita","family":"Sawhney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1429-6012","authenticated-orcid":false,"given":"Clare","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1248-9603","authenticated-orcid":false,"given":"Jackson","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6806-3188","authenticated-orcid":false,"given":"Magdaliz","family":"Gorritz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7065-9607","authenticated-orcid":false,"given":"Chi-Chang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2623-2053","authenticated-orcid":false,"given":"Jeetvan","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"issue":"3","key":"3102_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"3102_CR2","unstructured":"Fund WCR (2025) Prostate Cancer Statistics. https:\/\/www.wcrf.org\/preventing-cancer\/cancer-statistics\/prostate-cancer-statistics\/. Accessed September 26 2025"},{"issue":"1","key":"3102_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN et al (2025) Jemal A (2025) Cancer statistics. CA Cancer J Clin 75(1):10\u201345. https:\/\/doi.org\/10.3322\/caac.21871","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"3102_CR4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.clgc.2016.08.018","volume":"15","author":"DM Moreira","year":"2017","unstructured":"Moreira DM, Howard LE, Sourbeer KN et al (2017) Predicting time from metastasis to overall survival in castration-resistant prostate cancer: results from SEARCH. Clin Genitourin Cancer 15(1):60-66.e62. https:\/\/doi.org\/10.1016\/j.clgc.2016.08.018","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"3102_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0227552","volume":"15","author":"J Meht\u00e4l\u00e4","year":"2020","unstructured":"Meht\u00e4l\u00e4 J, Zong J, Vassilev Z et al (2020) Overall survival and second primary malignancies in men with metastatic prostate cancer. PLoS ONE 15(2):e0227552. https:\/\/doi.org\/10.1371\/journal.pone.0227552","journal-title":"PLoS ONE"},{"key":"3102_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113467","author":"A Jang","year":"2020","unstructured":"Jang A, Sartor O, Barata PC et al (2020) Therapeutic potential of PARP inhibitors in the treatment of metastatic castration-resistant prostate cancer. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers12113467","journal-title":"Cancers (Basel)"},{"issue":"10","key":"3102_CR7","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/s1470-2045(12)70379-0","volume":"13","author":"K Fizazi","year":"2012","unstructured":"Fizazi K, Scher HI, Molina A et al (2012) COU-AA-301 Investigators, Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13(10):983\u2013992. https:\/\/doi.org\/10.1016\/s1470-2045(12)70379-0","journal-title":"Lancet Oncol"},{"issue":"2","key":"3102_CR8","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/s1470-2045(14)71205-7","volume":"16","author":"CJ Ryan","year":"2015","unstructured":"Ryan CJ, Smith MR, Fizazi K et al (2015) COU-AA-302 Investigators, Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16(2):152\u2013160. https:\/\/doi.org\/10.1016\/s1470-2045(14)71205-7","journal-title":"Lancet Oncol"},{"issue":"9747","key":"3102_CR9","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/s0140-6736(10)61389-x","volume":"376","author":"JS de Bono","year":"2010","unstructured":"de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376(9747):1147\u20131154. https:\/\/doi.org\/10.1016\/s0140-6736(10)61389-x","journal-title":"Lancet"},{"key":"3102_CR10","doi-asserted-by":"crossref","unstructured":"Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New England Journal of Medicine. 2010 Jul 29;363(5):411-22.","DOI":"10.1056\/NEJMoa1001294"},{"key":"3102_CR11","doi-asserted-by":"crossref","unstructured":"Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fl\u00e9chon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS, AFFIRM Investigators (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367 (10\/5\/2012):1187\u20131197","DOI":"10.1056\/NEJMoa1207506"},{"issue":"2","key":"3102_CR12","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.eururo.2016.07.032","volume":"71","author":"TM Beer","year":"2017","unstructured":"Beer TM, Armstrong AJ, Rathkopf D et al (2017) Enzalutamide in men with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study. Eur Urol 71(2):151\u2013154. https:\/\/doi.org\/10.1016\/j.eururo.2016.07.032","journal-title":"Eur Urol"},{"key":"3102_CR13","doi-asserted-by":"publisher","unstructured":"de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Jr., Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fl\u00e9chon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI, COU-AA-Investigators (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364 (21):1995\u20132005. https:\/\/doi.org\/10.1056\/NEJMoa1014618","DOI":"10.1056\/NEJMoa1014618"},{"issue":"3","key":"3102_CR14","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D et al (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369(3):213\u2013223. https:\/\/doi.org\/10.1056\/NEJMoa1213755","journal-title":"N Engl J Med"},{"issue":"5","key":"3102_CR15","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.euf.2016.10.008","volume":"2","author":"D Lorente","year":"2016","unstructured":"Lorente D, Fizazi K, Sweeney C et al (2016) Optimal treatment sequence for metastatic castration-resistant prostate cancer. Eur Urol Focus 2(5):488\u2013498. https:\/\/doi.org\/10.1016\/j.euf.2016.10.008","journal-title":"Eur Urol Focus"},{"issue":"12","key":"3102_CR16","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN et al (2021) Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med 385(12):1091\u20131103. https:\/\/doi.org\/10.1056\/NEJMoa2107322","journal-title":"N Engl J Med"},{"issue":"6","key":"3102_CR17","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.8921","volume":"12","author":"M Sun","year":"2020","unstructured":"Sun M, Niaz MO, Nelson A et al (2020) Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer. Cureus 12(6):e8921. https:\/\/doi.org\/10.7759\/cureus.8921","journal-title":"Cureus"},{"issue":"10276","key":"3102_CR18","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/s0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S et al (2021) [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet 397(10276):797\u2013804. https:\/\/doi.org\/10.1016\/s0140-6736(21)00237-3","journal-title":"Lancet"},{"key":"3102_CR19","doi-asserted-by":"publisher","unstructured":"Sartor AO, Morris MJ, Chi KN, Bono JSD, Shore ND, Crosby M, Kreisl TN, Fizazi K (2022) PSMAfore: A phase 3 study to compare 177Lu-PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-na\u00efve patients with metastatic castration-resistant prostate cancer. J Clin Oncol 40 (6_suppl):TPS211-TPS211. https:\/\/doi.org\/10.1200\/JCO.2022.40.6_suppl.TPS211","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS211"},{"issue":"4","key":"3102_CR20","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.clgc.2019.12.019","volume":"18","author":"DJ George","year":"2020","unstructured":"George DJ, Sartor O, Miller K et al (2020) Treatment patterns and outcomes in patients with metastatic castration-resistant prostate cancer in a real-world clinical practice setting in the United States. Clin Genitourin Cancer 18(4):284\u2013294. https:\/\/doi.org\/10.1016\/j.clgc.2019.12.019","journal-title":"Clin Genitourin Cancer"},{"key":"3102_CR21","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Prostate Cancer V.5.2026. \u00a9 National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed May 25, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"issue":"6","key":"3102_CR22","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/j.juro.2015.06.106","volume":"194","author":"ED Crawford","year":"2015","unstructured":"Crawford ED, Higano CS, Shore ND et al (2015) Treating patients with metastatic castration resistant prostate cancer: a comprehensive review of available therapies. J Urol 194(6):1537\u20131547. https:\/\/doi.org\/10.1016\/j.juro.2015.06.106","journal-title":"J Urol"},{"key":"3102_CR23","doi-asserted-by":"publisher","unstructured":"Ghantoji S, Yu C, Sawhney A, Byrne C, Tang J, Runeckles K, Patel J (2022) Real-world treatment patterns in the U.S. and trends pre-post CARD trial among patients with metastatic castration-resistant prostate cancer. J Clin Oncol 40 (16_suppl):e17024-e17024. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.e17024","DOI":"10.1200\/JCO.2022.40.16_suppl.e17024"},{"issue":"12","key":"3102_CR24","doi-asserted-by":"publisher","first-page":"e2448707","DOI":"10.1001\/jamanetworkopen.2024.48707","volume":"7","author":"N Agarwal","year":"2024","unstructured":"Agarwal N, George DJ, Klaassen Z et al (2024) Physician Reasons for or Against Treatment Intensification in Patients With Metastatic Prostate Cancer. JAMA Netw Open 7(12):e2448707. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.48707","journal-title":"JAMA Netw Open"},{"key":"3102_CR25","unstructured":"Ismail U, Killeen RB (2024) Taxane toxicity. In: StatPearls. StatPearls Publishing"},{"key":"3102_CR26","unstructured":"Copyright \u00a9 2024, StatPearls Publishing LLC., Treasure Island (FL), USA,"},{"issue":"1","key":"3102_CR27","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1001\/jamaoncol.2016.3000","volume":"3","author":"ES de Morr\u00e9e","year":"2017","unstructured":"de Morr\u00e9e ES, Vogelzang NJ, Petrylak DP et al (2017) Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post Hoc Analysis of the Mainsail Study. JAMA Oncol 3(1):68\u201375. https:\/\/doi.org\/10.1001\/jamaoncol.2016.3000","journal-title":"JAMA Oncol"},{"issue":"3","key":"3102_CR28","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/ajco.13441","volume":"17","author":"M Takai","year":"2021","unstructured":"Takai M, Kato S, Nakano M et al (2021) Efficacy of cabazitaxel and the influence of clinical factors on the overall survival of patients with castration-resistant prostate cancer: A local experience of a multicenter retrospective study. Asia Pac J Clin Oncol 17(3):238\u2013244. https:\/\/doi.org\/10.1111\/ajco.13441","journal-title":"Asia Pac J Clin Oncol"},{"issue":"2","key":"3102_CR29","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1136\/ejhpharm-2019-001955","volume":"28","author":"L Al-Mansouri","year":"2021","unstructured":"Al-Mansouri L, Arasaratnam M, Gurney H (2021) Continuing cabazitaxel beyond 10 cycles for metastatic castrate-resistant prostate cancer: is there a benefit? Eur J Hosp Pharm 28(2):83\u201387. https:\/\/doi.org\/10.1136\/ejhpharm-2019-001955","journal-title":"Eur J Hosp Pharm"},{"issue":"15","key":"3102_CR30","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351(15):1502\u20131512. https:\/\/doi.org\/10.1056\/NEJMoa040720","journal-title":"N Engl J Med"},{"issue":"5","key":"3102_CR31","doi-asserted-by":"publisher","first-page":"192.e191","DOI":"10.1016\/j.urolonc.2022.01.009","volume":"40","author":"B Shayegan","year":"2022","unstructured":"Shayegan B, Wallis CJD, Malone S et al (2022) Real-world use of systemic therapies in men with metastatic castration resistant prostate cancer (mCRPC) in Canada. Urol Oncol 40(5):192.e191-192.e199. https:\/\/doi.org\/10.1016\/j.urolonc.2022.01.009","journal-title":"Urol Oncol"},{"issue":"9","key":"3102_CR32","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3109\/07357907.2014.958233","volume":"32","author":"D Beatrice","year":"2014","unstructured":"Beatrice D, Davide F, Calogero S et al (2014) Docetaxel in castration-resistant prostate cancer: a single-centre experience. Cancer Invest 32(9):445\u2013450. https:\/\/doi.org\/10.3109\/07357907.2014.958233","journal-title":"Cancer Invest"},{"issue":"2","key":"3102_CR33","doi-asserted-by":"publisher","first-page":"e281","DOI":"10.1016\/j.clgc.2016.08.019","volume":"15","author":"P Kongsted","year":"2017","unstructured":"Kongsted P, Svane IM, Lindberg H et al (2017) Clinical impact of the number of treatment cycles in first-line docetaxel for patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer 15(2):e281\u2013e287. https:\/\/doi.org\/10.1016\/j.clgc.2016.08.019","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"3102_CR34","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.prnil.2015.03.002","volume":"3","author":"DMC Poon","year":"2015","unstructured":"Poon DMC, Ng J, Chan K (2015) Importance of cycles of chemotherapy and postdocetaxel novel therapies in metastatic castration-resistant prostate cancer. Prostate Int 3(2):51\u201355. https:\/\/doi.org\/10.1016\/j.prnil.2015.03.002","journal-title":"Prostate Int"},{"issue":"1","key":"3102_CR35","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41391-022-00514-9","volume":"26","author":"B Shayegan","year":"2023","unstructured":"Shayegan B, Wallis CJD, Hamilton RJ et al (2023) Real-world utilization and outcomes of docetaxel among older men with metastatic prostate cancer: a retrospective population-based cohort study in Canada. Prostate Cancer Prostatic Dis 26(1):74\u201379. https:\/\/doi.org\/10.1038\/s41391-022-00514-9","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"3102_CR36","doi-asserted-by":"publisher","first-page":"157","DOI":"10.4111\/kju.2013.54.3.157","volume":"54","author":"SC Park","year":"2013","unstructured":"Park SC, Lee JW, Seo IY et al (2013) Predictive factors for premature discontinuation of docetaxel-based systemic chemotherapy in men with castration-resistant prostate cancer. Korean J Urol 54(3):157\u2013162. https:\/\/doi.org\/10.4111\/kju.2013.54.3.157","journal-title":"Korean J Urol"},{"issue":"1","key":"3102_CR37","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/aja.2012.110","volume":"15","author":"YY Qu","year":"2013","unstructured":"Qu YY, Dai B, Kong YY et al (2013) Prognostic factors in Chinese patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy. Asian J Androl 15(1):110\u2013115. https:\/\/doi.org\/10.1038\/aja.2012.110","journal-title":"Asian J Androl"},{"issue":"5\u20136","key":"3102_CR38","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000510900","volume":"65","author":"Y Nakai","year":"2020","unstructured":"Nakai Y, Tanaka N, Ichikawa K et al (2020) Appropriate number of docetaxel cycles in castration-resistant prostate cancer patients considering peripheral neuropathy and oncological control. Chemotherapy 65(5\u20136):119\u2013124. https:\/\/doi.org\/10.1159\/000510900","journal-title":"Chemotherapy"},{"issue":"14","key":"3102_CR39","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1002\/pros.23884","volume":"79","author":"M Tanaka","year":"2019","unstructured":"Tanaka M, Kimura T, Iwamura Y et al (2019) No survival benefit found after extended treatment with docetaxel for patients with castration-resistant prostate cancer. Prostate 79(14):1604\u20131610. https:\/\/doi.org\/10.1002\/pros.23884","journal-title":"Prostate"},{"issue":"4","key":"3102_CR40","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s12032-019-1257-1","volume":"36","author":"M Shiota","year":"2019","unstructured":"Shiota M, Nakamura M, Yokomizo A et al (2019) Efficacy and safety of cabazitaxel for castration-resistant prostate cancer in patients with > 10 cycles of docetaxel chemotherapy: a multi-institutional study. Med Oncol 36(4):32. https:\/\/doi.org\/10.1007\/s12032-019-1257-1","journal-title":"Med Oncol"},{"issue":"9","key":"3102_CR41","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.kjms.2016.07.012","volume":"32","author":"YC Shen","year":"2016","unstructured":"Shen YC, Chiang PH, Luo HL et al (2016) Determine of the optimal number of cycles of docetaxel in the treatment of metastatic castration-resistant prostate cancer. Kaohsiung J Med Sci 32(9):458\u2013463. https:\/\/doi.org\/10.1016\/j.kjms.2016.07.012","journal-title":"Kaohsiung J Med Sci"},{"issue":"8","key":"3102_CR42","doi-asserted-by":"publisher","first-page":"4411","DOI":"10.21873\/anticanres.13612","volume":"39","author":"M Shiota","year":"2019","unstructured":"Shiota M, Nakamura M, Yokomizo A et al (2019) Therapeutic Outcome of >10 Cycles of Cabazitaxel for Castration-resistant Prostate Cancer: A Multi-institutional Study. Anticancer Res 39(8):4411\u20134414. https:\/\/doi.org\/10.21873\/anticanres.13612","journal-title":"Anticancer Res"},{"issue":"1","key":"3102_CR43","doi-asserted-by":"publisher","first-page":"83","DOI":"10.31662\/jmaj.2021-0163","volume":"5","author":"T Matsumoto","year":"2022","unstructured":"Matsumoto T, Shiota M, Yamada S et al (2022) Anticancer effect of second-line treatment for castration-resistant prostate cancer following first-line treatment with androgen receptor pathway inhibitors. JMA J 5(1):83\u201390. https:\/\/doi.org\/10.31662\/jmaj.2021-0163","journal-title":"JMA J"},{"issue":"6","key":"3102_CR44","doi-asserted-by":"publisher","first-page":"e1073","DOI":"10.1016\/j.clgc.2017.07.016","volume":"15","author":"N Matsubara","year":"2017","unstructured":"Matsubara N, Yamada Y, Tabata KI et al (2017) Comparison of sequential treatment with androgen receptor-targeted agent followed by another androgen receptor-targeted agent versus androgen receptor-targeted agent followed by docetaxel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer 15(6):e1073\u2013e1080. https:\/\/doi.org\/10.1016\/j.clgc.2017.07.016","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"3102_CR45","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.clgc.2017.11.007","volume":"16","author":"H Miyake","year":"2018","unstructured":"Miyake H, Sugiyama T, Aki R et al (2018) Comparison of alternative androgen receptor-axis-targeted Agent (ARATA) and docetaxel as second-line therapy for patients with metastatic castration-resistant prostate cancer with progression after initial ARATA in real-world clinical practice in Japan. Clin Genitourin Cancer 16(3):219\u2013225. https:\/\/doi.org\/10.1016\/j.clgc.2017.11.007","journal-title":"Clin Genitourin Cancer"},{"issue":"11","key":"3102_CR46","doi-asserted-by":"publisher","first-page":"500.e501","DOI":"10.1016\/j.urolonc.2018.08.002","volume":"36","author":"WK Oh","year":"2018","unstructured":"Oh WK, Cheng WY, Miao R et al (2018) Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncology setting. Urol Oncol 36(11):500.e501-500.e509. https:\/\/doi.org\/10.1016\/j.urolonc.2018.08.002","journal-title":"Urol Oncol"},{"issue":"1","key":"3102_CR47","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/jjco\/hyad128","volume":"54","author":"N Matsubara","year":"2024","unstructured":"Matsubara N, Matsuyama H, Kazama H et al (2024) Baseline characteristics may impact treatment duration of cabazitaxel in patients with mCRPC: a subanalysis of data from a post-marketing surveillance. Jpn J Clin Oncol 54(1):97\u2013102. https:\/\/doi.org\/10.1093\/jjco\/hyad128","journal-title":"Jpn J Clin Oncol"},{"issue":"6","key":"3102_CR48","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/coc.0000000000001087","volume":"47","author":"Z Chakrani","year":"2024","unstructured":"Chakrani Z, Mellgard G, Saffran N et al (2024) Risk factors for early treatment discontinuation due to toxicity among patients with metastatic castration-resistant prostate cancer receiving androgen receptor-targeted therapy. Am J Clin Oncol 47(6):271\u2013278. https:\/\/doi.org\/10.1097\/coc.0000000000001087","journal-title":"Am J Clin Oncol"},{"issue":"10","key":"3102_CR49","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012816.pub2","volume":"10","author":"NJ Sathianathen","year":"2018","unstructured":"Sathianathen NJ, Philippou YA, Kuntz GM et al (2018) Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer. Cochrane Database Syst Rev 10(10):CD012816. https:\/\/doi.org\/10.1002\/14651858.CD012816.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"3102_CR50","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1684\/ejd.2016.2833","volume":"26","author":"V Sibaud","year":"2016","unstructured":"Sibaud V, Leboeuf NR, Roche H et al (2016) Dermatological adverse events with taxane chemotherapy. Eur J Dermatol 26(5):427\u2013443. https:\/\/doi.org\/10.1684\/ejd.2016.2833","journal-title":"Eur J Dermatol"},{"key":"3102_CR51","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.2147\/OTT.S297603","volume":"14","author":"JZ Cao","year":"2021","unstructured":"Cao JZ, Pan JF, Ng DM et al (2021) Maintenance Long-Term Multiple Cycles Treatment with Docetaxel in Metastatic Castration-Resistant Prostate Cancer: A Report of Three Cases. Onco Targets Ther 14:2797\u20132803. https:\/\/doi.org\/10.2147\/OTT.S297603","journal-title":"Onco Targets Ther"},{"issue":"12","key":"3102_CR52","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1111\/iju.15550","volume":"31","author":"H Miura","year":"2024","unstructured":"Miura H, Hatakeyama S, Tabata R et al (2024) Treatment trends in patients with de novo metastatic prostate cancer in the era of upfront combination therapy. Int J Urol 31(12):1330\u20131336. https:\/\/doi.org\/10.1111\/iju.15550","journal-title":"Int J Urol"},{"key":"3102_CR53","doi-asserted-by":"publisher","unstructured":"Mseke EP, Jessup B, Barnett T (2024) Impact of distance and\/or travel time on healthcare service access in rural and remote areas: A scoping review. Journal of Transport & Health 37. https:\/\/doi.org\/10.1016\/j.jth.2024.101819","DOI":"10.1016\/j.jth.2024.101819"},{"key":"3102_CR54","doi-asserted-by":"publisher","first-page":"243","DOI":"10.2147\/RRU.S385257","volume":"15","author":"S Ferretti","year":"2023","unstructured":"Ferretti S, Mercinelli C, Marandino L et al (2023) Metastatic Castration-Resistant Prostate Cancer: Insights on Current Therapy and Promising Experimental Drugs. Res Rep Urol 15:243\u2013259. https:\/\/doi.org\/10.2147\/RRU.S385257","journal-title":"Res Rep Urol"},{"key":"3102_CR55","doi-asserted-by":"publisher","first-page":"1158421","DOI":"10.3389\/fphar.2023.1158421","volume":"14","author":"Y Hua","year":"2023","unstructured":"Hua Y, Zou Y, Guan M et al (2023) Predictive model of chemotherapy-related toxicity in elderly Chinese cancer patients. Front Pharmacol 14:1158421. https:\/\/doi.org\/10.3389\/fphar.2023.1158421","journal-title":"Front Pharmacol"},{"issue":"10","key":"3102_CR56","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.39116","volume":"6","author":"JC Baltussen","year":"2023","unstructured":"Baltussen JC, de Glas NA, van Holstein Y et al (2023) Chemotherapy-related toxic effects and quality of life and physical functioning in older patients. JAMA Netw Open 6(10):e2339116. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.39116","journal-title":"JAMA Netw Open"},{"issue":"2","key":"3102_CR57","doi-asserted-by":"publisher","first-page":"53","DOI":"10.5980\/jpnjurol.112.53","volume":"112","author":"K Nishizawa","year":"2021","unstructured":"Nishizawa K, Hattahara K, Onishi H et al (2021) Cost analysis of androgen deprivation therapy and drugs for castration-resistant prostate cancer. Nihon Hinyokika Gakkai Zasshi 112(2):53\u201357. https:\/\/doi.org\/10.5980\/jpnjurol.112.53","journal-title":"Nihon Hinyokika Gakkai Zasshi"},{"key":"3102_CR58","doi-asserted-by":"publisher","unstructured":"Brady BL, Lucci M, Wilson K, Fox KM, Wojtynek J, Cooper C, Varker H, Chebili CL, Dokubo I (2021) Clinical and economic burden of intravenous paclitaxel or nab-paclitaxel for metastatic breast cancer. Am J Manag Care 27 (1 Spec. No.):Sp30-sp36. https:\/\/doi.org\/10.37765\/ajmc.2021.88561","DOI":"10.37765\/ajmc.2021.88561"},{"key":"3102_CR59","doi-asserted-by":"crossref","unstructured":"Triner D, Graf R, Gjoerup O, Tukachinsky H, Ross JS, Cheng HH, Pritchard CC, Zurita AJ, Mateo J, Cieslike M, Morgan TM (2024) Real-world effectiveness of PARP inhibitors (PARPi) in metastatic castration-resistant prostate cancer (mCRPC) by genomic homologous recombination repair (HRR) alterations and homologous recombination deficiency signature (HRDsig). J Clin Oncol 42 (4)","DOI":"10.1200\/JCO.2024.42.4_suppl.186"},{"key":"3102_CR60","doi-asserted-by":"publisher","unstructured":"Hennrich U, Eder M (2022) [(177)Lu]Lu-PSMA-617 (Pluvicto(TM)): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer. Pharmaceuticals (Basel) 15 (10). https:\/\/doi.org\/10.3390\/ph15101292","DOI":"10.3390\/ph15101292"},{"key":"3102_CR61","unstructured":"Novartis Pharmaceuticals Corporation (2025) Pluvicto Prescribing Information."},{"key":"3102_CR62","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Prostate Cancer V.4.2024. \u00a9 National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed May 25, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."}],"updated-by":[{"DOI":"10.1007\/s10147-026-03194-w","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000}}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03102-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03102-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03102-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:27:10Z","timestamp":1790832430000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03102-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":62,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["3102"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03102-2","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"20 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The given name for Jennifer Nguyen was inadvertently omitted; this has now been updated.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s10147-026-03194-w","URL":"https:\/\/doi.org\/10.1007\/s10147-026-03194-w","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NS, CB, JT, MG, and C-CC received consulting fees from Novartis Pharmaceuticals Corporation during the conduct of the study and outside the submitted work. JN, BK, AS, and JP are employees of Novartis Pharmaceuticals Corporation.","order":1,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}